Crescent Biopharma shared its third-quarter results for 2026 and noted progress in its clinical trials.

Nov 12, 2026, 4:47 PM ETResultsRead the original at SEC EDGAR

Good for CBIO

Crescent completed CR-001 dose escalation with more than 125 patients dosed and started its CR-002 trial. This progress supports a more positive outlook, but the report gives no patient-response results yet.

CBIO · Crescent Biopharma, Inc.

AI read · Good for CBIO

The AI's read

These advances bring Crescent closer to sharing results from its cancer-drug trials. They show the programs are moving through testing, but the report does not yet show whether the drugs help patients. The first CR-001 results are expected in the first quarter of 2027, so the promise still depends on future findings.

Get alerts for CBIO

Follow Crescent Biopharma, Inc. (CBIO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CBIO

Free on the App Store and Google Play, or on the web.